Literature DB >> 20167662

Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study.

John W Gaubatz1, Christie M Ballantyne, Bruce A Wasserman, Max He, Lloyd E Chambless, Eric Boerwinkle, Ron C Hoogeveen.   

Abstract

OBJECTIVE: To examine the relationship of plasma levels of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase 1 (TIMP-1) with carotid artery characteristics measured by MRI in a cross-sectional investigation among Atherosclerosis Risk in Communities Carotid MRI Study participants. METHODS AND
RESULTS: A stratified random sample was recruited based on intima-media thickness from a previous ultrasonographic examination. A high-resolution gadolinium-enhanced MRI examination of the carotid artery was performed from 2004 to 2005 on 1901 Atherosclerosis Risk in Communities cohort participants. Multiple carotid wall characteristics, including wall thickness, lumen area, calcium area, lipid core, and fibrous cap measures, were evaluated for associations with plasma MMPs 1, 2, 3, 7, 8, and 9 and TIMP-1. Plasma MMPs 1, 3, and 7 were significantly higher among participants in the high intima-media thickness group compared with those in the low intima-media thickness group. The normalized wall index was independently associated with MMPs 3 and 7 and TIMP-1. MMP-7 was positively associated with carotid calcification. The mean fibrous cap thickness was significantly higher in individuals with elevated TIMP-1 levels. In addition, TIMP-1 was positively associated with measures of lipid core.
CONCLUSION: Circulating levels of specific MMPs and TIMP-1 were associated with carotid wall remodeling and structural changes related to plaque burden in elderly participants.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167662      PMCID: PMC2860383          DOI: 10.1161/ATVBAHA.109.195370

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  35 in total

Review 1.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

2.  Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure.

Authors:  P Altieri; C Brunelli; S Garibaldi; A Nicolino; S Ubaldi; P Spallarossa; L Olivotti; P Rossettin; A Barsotti; G Ghigliotti
Journal:  Eur J Clin Invest       Date:  2003-08       Impact factor: 4.686

3.  Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis.

Authors:  Y Noji; K Kajinami; M A Kawashiri; Y Todo; T Horita; A Nohara; T Higashikata; A Inazu; J Koizumi; T Takegoshi; H Mabuchi
Journal:  Clin Chem Lab Med       Date:  2001-05       Impact factor: 3.694

Review 4.  [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].

Authors:  J-L Beaudeux; P Giral; E Bruckert; M-J Foglietti; M J Chapman
Journal:  Ann Biol Clin (Paris)       Date:  2003 Mar-Apr       Impact factor: 0.459

5.  Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging initial results.

Authors:  Bruce A Wasserman; William I Smith; Hugh H Trout; Richard O Cannon; Robert S Balaban; Andrew E Arai
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

6.  Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.

Authors:  Zhaoxia Luan; Alex J Chase; Andrew C Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-27       Impact factor: 8.311

Review 7.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

8.  Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia.

Authors:  Jean-Louis Beaudeux; Philippe Giral; Eric Bruckert; Marguy Bernard; Marie-José Foglietti; M John Chapman
Journal:  Atherosclerosis       Date:  2003-07       Impact factor: 5.162

9.  TIMP-1 stimulates proliferation of human aortic smooth muscle cells and Ras effector pathways.

Authors:  Takemi Akahane; Manabu Akahane; Amy Shah; Unnur P Thorgeirsson
Journal:  Biochem Biophys Res Commun       Date:  2004-11-05       Impact factor: 3.575

10.  Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease.

Authors:  Ji Won Son; Kwang Kon Koh; Jeong Yeal Ahn; Dong Kyu Jin; Gi Soo Park; Dae Sung Kim; Eak Kyun Shin
Journal:  Int J Cardiol       Date:  2003-03       Impact factor: 4.164

View more
  16 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

3.  Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.

Authors:  Rajashree Rana; Tianfang Huang; Georgios Koukos; Elizabeth K Fletcher; Susan E Turner; Andrew Shearer; Paul A Gurbel; Jeffrey J Rade; Carey D Kimmelstiel; Kevin P Bliden; Lidija Covic; Athan Kuliopulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-04-05       Impact factor: 8.311

Review 4.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

5.  Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study.

Authors:  Salim S Virani; Diane J Catellier; Lisa A Pompeii; Vijay Nambi; Ron C Hoogeveen; Bruce A Wasserman; Josef Coresh; Thomas H Mosley; James D Otvos; A Richey Sharrett; Eric Boerwinkle; Christie M Ballantyne
Journal:  Atherosclerosis       Date:  2011-08-07       Impact factor: 5.162

Review 6.  The autoimmune concept of atherosclerosis.

Authors:  Cecilia Grundtman; Georg Wick
Journal:  Curr Opin Lipidol       Date:  2011-10       Impact factor: 4.776

7.  Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis.

Authors:  Karyn M Austin; Nga Nguyen; Golrokh Javid; Lidija Covic; Athan Kuliopulos
Journal:  J Biol Chem       Date:  2013-06-27       Impact factor: 5.157

8.  Icariside II attenuates cerebral ischemia/reperfusion-induced blood-brain barrier dysfunction in rats via regulating the balance of MMP9/TIMP1.

Authors:  Mu-Bo Liu; Wei Wang; Jian-Mei Gao; Fei Li; Jing-Shan Shi; Qi-Hai Gong
Journal:  Acta Pharmacol Sin       Date:  2020-06-02       Impact factor: 6.150

9.  Plasma matrix metalloproteinases and postmenopausal breast cancer risk: a nested case-control study in the Multiethnic Cohort study.

Authors:  Yeonju Kim; Nicholas J Ollberding; Yurii B Shvetsov; Adrian A Franke; Lynne R Wilkens; Gertraud Maskarinec; Brenda Y Hernandez; Loïc Le Marchand; Brian E Henderson; Laurence N Kolonel; Marc T Goodman
Journal:  Breast Cancer Res Treat       Date:  2012-10-31       Impact factor: 4.872

Review 10.  Matrix metalloproteases and PAR1 activation.

Authors:  Karyn M Austin; Lidija Covic; Athan Kuliopulos
Journal:  Blood       Date:  2012-10-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.